AC Immune jumps after US FDA grants fast-track status for Parkinson's disease drug

AC Immune AG

11/08/2026 12:23

** Shares of Switzerland-based drug developer AC Immune ACIU.O rise 6.1% to $2.42 premarket 
** Company says the U.S. FDA granted a fast-track tag to its experimental drug ACI-7104, to treat early Parkinson's disease
** FDA's fast-track tag is meant to speed up development and review of treatments for serious diseases with unmet medical needs
** The drug is currently in mid-stage testing, with trial results expected to be announced in the second half of 2026
** Parkinson's disease is a slow brain disorder that affects mobility when brain cells stop making a chemical called dopamine
** Up to last close, the stock is down 27.4% YTD

(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))